The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
Blog
Since the start of the pandemic, Johnson & Johnson has been working to help address the devastating impacts of COVID-19 through the power of its science, the size of its global reach—and the know-how that comes from such experiences as standing up to challenges like HIV.
Staying connected is more important than ever for all of us around the world, and in both our personal and professional lives. Enter wireless technology: It’s helping us keep in touch with friends and family, as well as work and learn remotely. It’s also supporting life-saving telemedicine and is instrumental in getting people food and other immediate resources.
In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
In Episode 2, Lisa Ling talks with Dr. Francis Collins, Director, NIH about the latest on treatments and vaccines. Also, Harvard's Dr. Ashish Jha shares how the virus affects the body and Johns Hopkins' Dr. Tom Inglesby explains what the new data on spread means for people.
In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
In the Season 2 premiere, Lisa Ling checks into the AIDS 2020 conference to talk with HIV advocate Laverne Cox and Johnson &. Johnson Chief Scientific Officer Paul Stoffels, M.D., about how HIV vaccine research is informing work on COVID-19 vaccines.
While the COVID-19 pandemic has created so much uncertainty, we remain committed to supporting people living with substance use disorders and schizophrenia and helping to assure that patients have access to our medicines.
Medtronic CEO talks with TriplePundit about delivering on our Mission during a pandemic
Article
CEO Geoff Martha was recently interviewed by TriplePundit about the company's response to COVID-19. Watch clips of the conversation, where he discusses how our Mission guided him and empowered us to put purpose over profit in a time of crisis.
Though we are separated by distance, the world is coming together to fight coronavirus
Article
Coronavirus reminds us how our economies, industries, rituals, and life as we know it, exist in a delicate balance. What happens in one corner of the world inevitably impacts another. And seemingly overnight, those connections start to unravel. So while we continue to search for answers, we must find ways to help put things back together.
NEW YORK, July 9,2020 /3BL Media/ — Pharmaceutical and biotech companies are actively working to enhance their sustainability efforts to increase the emphasis on long-term value creation, stakeholder engagement, and forward-looking disclosures. To support these efforts, the Biopharma Sustainability Roundtable (BSRT) has formed a partnership with CECP’s CEO Investor Forum. Together, the two groups will co-host the first sector-specific CEO-Investor Forum in June 2021.
As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
Blog
As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
To effectively support the goal of access for all citizens, we must consider all citizens. But delivering on that goal takes a commitment to understanding deeply who patients are, their needs, and how we can best support positive health outcomes. We need to start at the beginning and build into every decision we make and step we take the diverse socio economic and individual health considerations of each person we encounter.
